What is the management of left posterior fascicular (LPF) block?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 2, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Management of left posterior fascicular block (LPFB) primarily focuses on identifying and treating the underlying cause, as LPFB itself is typically asymptomatic and doesn't require specific treatment. The first step is to conduct a thorough cardiac evaluation including a 12-lead ECG, echocardiogram, and possibly cardiac MRI to assess for structural heart disease, as outlined in the 2018 ACC/AHA/HRS guideline on the evaluation and management of patients with bradycardia and cardiac conduction delay 1.

Key Considerations

  • If LPFB is associated with coronary artery disease, management includes standard therapies such as aspirin (81-325 mg daily), statins (e.g., atorvastatin 20-80 mg daily), beta-blockers (e.g., metoprolol 25-200 mg daily), and ACE inhibitors (e.g., lisinopril 5-40 mg daily).
  • For LPFB related to cardiomyopathy, treatment involves addressing heart failure with medications like beta-blockers, ACE inhibitors, diuretics (e.g., furosemide 20-80 mg daily), and aldosterone antagonists (e.g., spironolactone 25-50 mg daily), as per the guidelines 1.

Monitoring and Follow-Up

  • Regular cardiac monitoring is essential, with follow-up ECGs every 6-12 months to detect progression to more complex conduction disorders.
  • Unlike other fascicular blocks, LPFB rarely progresses to complete heart block, so prophylactic pacemaker implantation is not typically indicated unless there are other conduction abnormalities present, as suggested by the guidelines 1.

Clinical Implications

  • The presence of LPFB may indicate more extensive cardiac disease, as it's less common than left anterior fascicular block and often associated with more significant myocardial damage.
  • A thorough evaluation and management plan should be tailored to the individual patient's needs, taking into account the underlying cause of LPFB and any associated cardiac conditions, as recommended by the 2018 ACC/AHA/HRS guideline 1.

From the Research

Management of Left Posterior Fascicular Block

The management of left posterior fascicular block (LPFB) can be complex and depends on the underlying cause and associated conditions.

  • In cases of verapamil-sensitive idiopathic left ventricular tachycardia (ILVT), radiofrequency ablation can be an effective treatment, with the creation of a left posterior fascicular block used as an endpoint for successful ablation 2.
  • The use of beta-blockers and ACE inhibitors has been shown to be effective in managing various cardiovascular conditions, including hypertension, arrhythmias, and heart failure, and may be beneficial in patients with LPFB 3, 4.
  • In patients presenting with ventricular tachyarrhythmia, treatment with beta-blockers or ACE inhibitors has been associated with improved survival 4.
  • The diagnosis and management of LPFB should consider the clinical aspects and electrocardiographic findings, as well as the presence of any underlying conditions that may be contributing to the block 5.
  • In some cases, LPFB may be associated with other conduction disorders, such as left septal fascicular block, and management may need to be tailored to the individual patient's condition 6.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Left posterior fascicular block, state-of-the-art review: A 2018 update.

Indian pacing and electrophysiology journal, 2018

Research

Unusual conduction disorder: left posterior fascicular block + left septal fascicular block.

Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc, 2015

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.